Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 0.54 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.49 |
| ▸ | CDK4 | P11802 | 3/20 | 0.44 |
| ▸ | CCND3 | P30281 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30111133 | 1.00 | PTPN11 (0.54) | PTPN11MAPK3MAPK1KCNH2CDK4 | |
| SCHEMBL24878906 | 1.00 | PTPN11 (0.54) | PTPN11MAPK3MAPK1KCNH2CDK4 | |
| SCHEMBL24878748 | 0.91 | PTPN11 (0.62) | PTPN11MAPK3MAPK1KCNH2 | |
| SCHEMBL30110972 | 0.91 | PTPN11 (0.62) | PTPN11MAPK3MAPK1KCNH2 | |
| SCHEMBL24878872 | 0.91 | PTPN11 (0.62) | PTPN11MAPK3MAPK1KCNH2 | |
| SCHEMBL24879124 | 0.91 | PTPN11 (0.62) | PTPN11MAPK3MAPK1KCNH2 | |
| SCHEMBL30111268 | 0.91 | PTPN11 (0.62) | PTPN11MAPK3MAPK1KCNH2 | |
| SCHEMBL30987334 | 0.89 | PTPN11 (0.53) | PTPN11MAPK3MAPK1KCNH2CDK4 | |
| SCHEMBL24879085 | 0.89 | PTPN11 (0.54) | PTPN11MAPK3MAPK1KCNH2CDK4 | |
| SCHEMBL30111100 | 0.89 | PTPN11 (0.54) | PTPN11MAPK3MAPK1KCNH2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| CN-117916242-A | SHP2 inhibitors and uses thereof | 治纳辅医药科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023282702-A1 | SHP2 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | PTPN11 16/4885MAPK3 389/4885MAPK1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.